Free Trial
NASDAQ:APLS

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

Apellis Pharmaceuticals logo
$24.33 +0.60 (+2.53%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$23.72 -0.61 (-2.53%)
As of 08/7/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Key Stats

Today's Range
$23.23
$24.42
50-Day Range
$16.91
$24.33
52-Week Range
$16.10
$41.94
Volume
2.60 million shs
Average Volume
2.86 million shs
Market Capitalization
$3.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.83
Consensus Rating
Moderate Buy

Company Overview

Apellis Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

APLS MarketRank™: 

Apellis Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 64th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 10 buy ratings, 9 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Apellis Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Apellis Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.70) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Apellis Pharmaceuticals is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Apellis Pharmaceuticals is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Apellis Pharmaceuticals has a P/B Ratio of 19.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.06% of the outstanding shares of Apellis Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Apellis Pharmaceuticals has recently decreased by 36.94%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Apellis Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Apellis Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.06% of the outstanding shares of Apellis Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Apellis Pharmaceuticals has recently decreased by 36.94%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Apellis Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 32 news articles for Apellis Pharmaceuticals this week, compared to 9 articles on an average week.
  • Search Interest

    24 people have searched for APLS on MarketBeat in the last 30 days. This is an increase of 243% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,403,832.00 in company stock.

  • Percentage Held by Insiders

    Only 6.50% of the stock of Apellis Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Apellis Pharmaceuticals' insider trading history.
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $37.78
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00
See More Headlines

APLS Stock Analysis - Frequently Asked Questions

Apellis Pharmaceuticals' stock was trading at $31.91 at the start of the year. Since then, APLS stock has decreased by 23.8% and is now trading at $24.33.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings data on Thursday, July, 31st. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.11. Apellis Pharmaceuticals's revenue for the quarter was down 10.6% compared to the same quarter last year.
Read the conference call transcript
.

Apellis Pharmaceuticals subsidiaries include Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and more.

Apellis Pharmaceuticals (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Top institutional shareholders of Apellis Pharmaceuticals include Jennison Associates LLC (2.12%), Y Intercept Hong Kong Ltd (0.13%), Bank of Montreal Can (0.13%) and CWM LLC (0.10%). Insiders that own company stock include Pascal Deschatelets, Alec Machiels, Cedric Francois, David O Watson, Timothy Eugene Sullivan, A Sinclair Dunlop, Federico Grossi, Adam J Townsend, Mark Jeffrey Delong, Nur Nicholson, Lukas Scheibler, Jeffrey Eisele, Caroline Baumal, James George Chopas and Karen Lewis.
View institutional ownership trends
.

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/31/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APLS
CIK
1492422
Fax
N/A
Employees
770
Year Founded
2009

Price Target and Rating

High Price Target
$83.00
Low Price Target
$19.00
Potential Upside/Downside
+51.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
20 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$197.88 million
Net Margins
-30.24%
Pretax Margin
-30.01%
Return on Equity
-116.09%
Return on Assets
-26.72%

Debt

Debt-to-Equity Ratio
2.90
Current Ratio
3.77
Quick Ratio
3.16

Sales & Book Value

Annual Sales
$781.37 million
Price / Sales
3.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.24 per share
Price / Book
19.62

Miscellaneous

Outstanding Shares
126,290,000
Free Float
118,081,000
Market Cap
$3.07 billion
Optionable
Optionable
Beta
0.78

Social Links

10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:APLS) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners